Adviser Investments LLC boosted its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 2.4% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 66,792 shares of the biopharmaceutical company’s stock after purchasing an additional 1,571 shares during the period. Adviser Investments LLC’s holdings in Gilead Sciences were worth $5,411,000 at the end of the most recent reporting period.
A number of other institutional investors also recently made changes to their positions in the business. Sanders Capital LLC bought a new stake in Gilead Sciences in the third quarter worth $427,585,000. Renaissance Technologies LLC boosted its holdings in Gilead Sciences by 35.0% in the second quarter. Renaissance Technologies LLC now owns 10,407,848 shares of the biopharmaceutical company’s stock worth $736,667,000 after acquiring an additional 2,700,600 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of Gilead Sciences by 2.4% during the second quarter. Vanguard Group Inc. now owns 92,841,960 shares of the biopharmaceutical company’s stock valued at $6,571,355,000 after purchasing an additional 2,148,697 shares in the last quarter. The Manufacturers Life Insurance Company lifted its holdings in shares of Gilead Sciences by 50.0% during the second quarter. The Manufacturers Life Insurance Company now owns 6,191,622 shares of the biopharmaceutical company’s stock valued at $438,244,000 after purchasing an additional 2,062,886 shares in the last quarter. Finally, BlackRock Inc. lifted its holdings in shares of Gilead Sciences by 1.9% during the second quarter. BlackRock Inc. now owns 104,906,494 shares of the biopharmaceutical company’s stock valued at $7,425,281,000 after purchasing an additional 1,937,031 shares in the last quarter. 75.94% of the stock is currently owned by institutional investors and hedge funds.
In other news, EVP Gregg H. Alton sold 15,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 1st. The stock was sold at an average price of $74.82, for a total value of $1,122,300.00. Following the completion of the sale, the executive vice president now directly owns 77,363 shares in the company, valued at $5,788,299.66. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider John C. Martin sold 50,000 shares of the company’s stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $73.62, for a total value of $3,681,000.00. Following the completion of the sale, the insider now owns 3,046,766 shares of the company’s stock, valued at $224,302,912.92. The disclosure for this sale can be found here. In the last 90 days, insiders sold 461,666 shares of company stock valued at $34,072,567. 1.30% of the stock is owned by company insiders.
GILD has been the topic of a number of research analyst reports. Vetr raised Gilead Sciences from a “buy” rating to a “strong-buy” rating and set a $91.98 price target on the stock in a report on Friday, October 13th. Berenberg Bank set a $96.00 price objective on Gilead Sciences and gave the company a “buy” rating in a research report on Thursday, October 19th. BMO Capital Markets reduced their price target on Gilead Sciences from $89.00 to $83.00 and set an “outperform” rating for the company in a research report on Friday, October 27th. Credit Suisse Group restated a “buy” rating and issued a $82.00 price target on shares of Gilead Sciences in a research report on Thursday, December 7th. Finally, Mizuho upped their price target on Gilead Sciences from $77.00 to $83.00 and gave the stock a “buy” rating in a research report on Wednesday, November 8th. Two investment analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Gilead Sciences currently has an average rating of “Buy” and an average target price of $85.03.
Shares of Gilead Sciences, Inc. (NASDAQ GILD) traded down $0.04 during mid-day trading on Friday, hitting $79.02. The stock had a trading volume of 6,342,448 shares, compared to its average volume of 8,150,000. The firm has a market cap of $103,190.00, a PE ratio of 8.99, a PEG ratio of -1.68 and a beta of 1.13. The company has a current ratio of 3.68, a quick ratio of 3.56 and a debt-to-equity ratio of 1.10. Gilead Sciences, Inc. has a fifty-two week low of $63.76 and a fifty-two week high of $86.27.
Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.13 by $0.14. Gilead Sciences had a return on equity of 57.15% and a net margin of 42.22%. The business had revenue of $6.51 billion during the quarter, compared to analysts’ expectations of $6.40 billion. During the same quarter in the previous year, the firm posted $2.75 EPS. The company’s revenue for the quarter was down 13.2% on a year-over-year basis. research analysts expect that Gilead Sciences, Inc. will post 8.53 EPS for the current year.
The firm also recently declared a quarterly dividend, which was paid on Thursday, December 28th. Investors of record on Friday, December 15th were paid a $0.52 dividend. The ex-dividend date of this dividend was Thursday, December 14th. This represents a $2.08 annualized dividend and a dividend yield of 2.63%. Gilead Sciences’s dividend payout ratio is presently 23.66%.
ILLEGAL ACTIVITY WARNING: “Gilead Sciences, Inc. (NASDAQ:GILD) Position Boosted by Adviser Investments LLC” was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece of content on another website, it was stolen and reposted in violation of U.S. & international copyright law. The original version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/01/13/adviser-investments-llc-increases-stake-in-gilead-sciences-inc-gild.html.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.